Targeted Quantitative Plasma Metabolomics Identifies Metabolite Signatures that Distinguish Heart Failure with Reduced and Preserved Ejection Fraction
Fawaz Naeem(University of Pennsylvania), Daniel P. Kelly(Cardiovascular Institute of the South), Rachel J. Roth Flach(Pfizer (United States)), John D. Groarke(Edinburgh Cancer Research), Clarissa Shoffler(University of Pennsylvania), Donald Bennett(Pfizer (United States)), Iphigenia Tzameli(Pfizer (United States)), Daniel J. Rader(University of Pennsylvania), Christopher Petucci(University of Pennsylvania), Cheryl Tow‐Keogh(Pfizer (United States)), Teresa C. Leone(Cardiovascular Institute of the South), Ravindra C. Kodihalli(Pfizer (United States)), Jessica Mancuso(Pfizer (United States)), Tiffany Hidalgo(Pfizer (United States))
Cited by 2
Related Papers
Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes
|Nature Genetics|2006|2.3k
Myocarditis in Patients Treated With Immune Checkpoint Inhibitors
|Journal of the American College of Cardiology|2018|1.5k
Genetic Risk, Adherence to a Healthy Lifestyle, and Coronary Disease
|New England Journal of Medicine|2016|1.5k
Peroxisome proliferator–activated receptor γ coactivator-1 promotes cardiac mitochondrial biogenesis
|Journal of Clinical Investigation|2000|1.3k
A variant in CDKAL1 influences insulin response and risk of type 2 diabetes
|Nature Genetics|2007|1.1k